What does Tracon Pharma do?

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing targeted therapeutics for cancer. Founded in 2004, the company aimed to address unmet medical needs by creating product candidates that target cellular mechanisms involved in cancer growth and angiogenesis. TRACON emphasized developing therapies with favorable side effect profiles that could complement existing treatments. The company's clinical-stage product portfolio includes Envafolimab, a PD-L1 single-domain antibody for refractory soft tissue sarcoma, and YH001, a monoclonal antibody in Phase I trials for various cancer types. Other products in development include TRC102, a small molecule for mesothelioma and other solid tumors, and TJ004309, a CD73 antibody in Phase I development. Additionally, TRACON is working on bispecific antibodies in the preclinical stage.